Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H29FN4O5 |
| Molecular Weight | 556.5842 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N(C(=O)C(C(=O)NC2=CC(F)=C(OC3=C4C=CC(OCC(C)(C)O)=CC4=NC=C3)C=C2)=C1C)C5=CC=CC=C5
InChI
InChIKey=VQYYQSZNRVQLIS-UHFFFAOYSA-N
InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)
| Molecular Formula | C31H29FN4O5 |
| Molecular Weight | 556.5842 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 00:27:22 GMT 2025
by
admin
on
Wed Apr 02 00:27:22 GMT 2025
|
| Record UNII |
PW3Q92Z6A4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PW3Q92Z6A4
Created by
admin on Wed Apr 02 00:27:22 GMT 2025 , Edited by admin on Wed Apr 02 00:27:22 GMT 2025
|
PRIMARY | |||
|
300000005131
Created by
admin on Wed Apr 02 00:27:22 GMT 2025 , Edited by admin on Wed Apr 02 00:27:22 GMT 2025
|
PRIMARY | |||
|
1394820-69-9
Created by
admin on Wed Apr 02 00:27:22 GMT 2025 , Edited by admin on Wed Apr 02 00:27:22 GMT 2025
|
PRIMARY | |||
|
60165029
Created by
admin on Wed Apr 02 00:27:22 GMT 2025 , Edited by admin on Wed Apr 02 00:27:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MINOR
Vmax
|
||
|
TRANSPORTER -> NON-SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MAJOR
Km
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MAJOR
Vmax
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MINOR
Vmax
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MINOR
Km
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MINOR
Vmax
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
NINGETINIB M1 FORMATION
MINOR
Km
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: HEC Pharm; Class: Antineoplastic, Small molecule; Mechanism of Action: Axl receptor tyrosine kinase inhibitor, Fms-like tyrosine kinase 3 inhibitor, Proto oncogene protein c met inhibitor, Proto-oncogene protein c-mer inhibitor, RON protein inhibitor, Signal transduction pathway modulator, Vascular endothelial growth factor receptor-2 antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Glioblastoma; Most Recent Events: 11 Mar 2016 Phase-I clinical trials in Glioblastoma in China (PO), 03 Nov 2015 Ningetinib is still in phase I trials for Glioma in China (HEC Pharm pipeline, October 2015), 07 Apr 2014 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
|
